LTRN

Lantern Pharma Inc

Sep 16 • 04:00PM ET

4.10

+0.29 7.61 %

Healthcare • Biotechnology • USA • NASD

Peers: EXAI DNLI FATE IMTX KRYS RAPT RPTX XERS ARDX

| Held by: VTI VXF MEDX IWC DFSU DFAC DCOR DXUV

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	24.08%	Shs Outstand	10.78M	Perf Week	1.23%
Market Cap	44.28M	Forward P/E	-	EPS next Y	-1.97	Insider Trans	-10.83%	Shs Float	8.20M	Perf Month	-10.28%
Enterprise Value	28.53M	PEG	-	EPS next Q	-0.47	Inst Own	10.88%	Short Float	5.60%	Perf Quarter	28.12%
Income	-19.25M	P/S	-	EPS this Y	5.18%	Inst Trans	-4.24%	Short Ratio	1.85	Perf Half Y	4.33%
Sales	0.00M	P/B	3.53	EPS next Y	-7.65%	ROA	-72.63%	Short Interest	0.46M	Perf YTD	28.53%
Book/sh	1.16	P/C	2.79	EPS next 5Y	-2.53%	ROE	-88.59%	52W High	6.12 -32.98%	Perf Year	8.18%
Cash/sh	1.47	P/FCF	-	EPS past 3/5Y	-19.42% -37.87%	ROIC	-153.55%	52W Low	2.55 60.78%	Perf 3Y	-23.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.83% 8.21%	Perf 5Y	-72.17%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-8.47%	Oper. Margin	-	ATR (14)	0.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.41	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.52	EPS Q/Q	12.89%	SMA20	-1.62%	Beta	1.55	Target Price	25.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-3.25%	Rel Volume	2.89	Prev Close	3.81
Employees	24	LT Debt/Eq	0.00	Earnings	Aug 13 AMC	SMA200	7.19%	Avg Volume	248.34K	Price	4.10
IPO	Jun 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.09% -	Trades		Volume	718,257	Change	7.61%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

Today 08:29AM	Lantern Pharmas LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors (Business Wire) +7.61%
Sep-03-25 09:44AM	Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial (Business Wire) +6.45%
Aug-13-25 04:30PM	Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates (Business Wire) +6.97%
Aug-07-25 05:34AM	FDA clears Starlight Therapeutics IND for Phase Ib/IIa glioblastoma trial (Clinical Trials Arena)
Aug-06-25 08:30AM	Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial (Business Wire)
08:55AM	Loading…
Aug-04-25 08:55AM	Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai (Business Wire) +11.53%
Aug-01-25 05:45AM	Lantern Pharma concludes patient enrolment for trial of LP-300 in Japan (Clinical Trials Arena) +7.43%
Jul-31-25 07:30AM	Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic Clinical Trial in Japan for LP-300 (Business Wire) +10.72%
Jul-28-25 08:00AM	Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors (Business Wire) -5.31%
Jul-23-25 07:56AM	Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial (Business Wire)
Jul-21-25 08:20AM	Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy (Business Wire) -5.01%
Jul-16-25 08:30AM	IBN Initiates Coverage of Lantern Pharma Inc. (GlobeNewswire) +6.12%
Jul-15-25 09:40AM	Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment (Business Wire) -5.76%
Jun-16-25 08:30AM	Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years (Business Wire)
May-29-25 11:21PM	Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models (Insider Monkey) +9.06%
08:30AM	Loading…
08:30AM	Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials (Business Wire)
May-15-25 08:45AM	Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates (Business Wire)
May-12-25 09:00AM	Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need (Business Wire)
08:31AM	EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients (Benzinga)
May-08-25 08:30AM	Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET (Business Wire) -11.06%
May-05-25 08:55AM	Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC) (Business Wire)
08:31AM	EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial (Benzinga)
Apr-01-25 09:01PM	Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com) -6.50%
Mar-27-25 08:35PM	Lantern Pharma Inc. (LTRN) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results (Business Wire)
Mar-20-25 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET (Business Wire)
Mar-12-25 06:00AM	How long-term energy plays outshine short-term hype (Yahoo Finance Video) +7.56%
Feb-20-25 04:14PM	Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech (Insider Monkey) -6.68%
Feb-19-25 08:00AM	Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates (Business Wire)
Jan-27-25 06:54PM	Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies (Insider Monkey) -15.00%
07:55AM	Loading…
07:55AM	Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer (Business Wire)
Jan-17-25 01:29PM	Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development (Insider Monkey)
Dec-10-24 10:40AM	AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan (Insider Monkey)
Dec-09-24 12:21PM	Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial (Clinical Trials Arena)
08:15AM	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Dec-07-24 01:59AM	Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer (Insider Monkey)
Dec-03-24 08:00AM	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) (Business Wire)
Nov-26-24 08:45AM	Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
Nov-19-24 08:00AM	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Nov-08-24 06:03PM	Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Nov-05-24 08:00AM	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board (Business Wire)
Oct-31-24 08:00AM	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET (Business Wire)
Oct-23-24 08:45AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 (Business Wire)
Oct-21-24 08:00AM	Lantern Pharma to Host & Participate in Two Public Webinars During October (Business Wire)
Oct-15-24 09:07AM	Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA (Business Wire)
Oct-09-24 05:56PM	Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
Sep-23-24 08:00AM	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers (Business Wire)
Aug-31-24 02:02PM	Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-08-24 04:01PM	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire) -7.68%
Aug-07-24 09:31AM	Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 (Business Wire) +12.26%
Aug-05-24 08:00AM	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort (Business Wire) -5.88%
Aug-01-24 08:00AM	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET (Business Wire)
Jul-10-24 08:30AM	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 (Business Wire)
Jun-12-24 07:30AM	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 (Business Wire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-09-24 04:02PM	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.09% -9.54%
May-06-24 06:41AM	Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM	Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)
03:00AM	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism (Business Wire)
May-02-24 07:30AM	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM	3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM	Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM	Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com) +33.21%
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)
Nov-01-23 08:00AM	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET (Business Wire)
Oct-24-23 04:03PM	The 7 Most Undervalued AI Penny Stocks to Buy: October 2023 (InvestorPlace)
Oct-10-23 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET (Business Wire) +10.32%
Oct-03-23 08:00AM	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma (Business Wire) -8.23%
Sep-29-23 07:40AM	LTRN: Spotlight on LP-184 & 284 (Zacks)
Sep-25-23 08:30AM	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors (Business Wire)
Sep-18-23 09:00AM	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkins Lymphomas (Business Wire)
Sep-14-23 09:09AM	The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:00AM	Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkins Lymphomas at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Aug-28-23 05:32PM	3 AI Stocks That Still Trade Under $10 Per Share (InvestorPlace)
08:00AM	Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors (Business Wire)
Aug-23-23 06:00PM	The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023 (InvestorPlace)
Aug-14-23 08:30AM	Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT (Business Wire)
Aug-10-23 08:37AM	LTRN: 2Q:23 Quarterly Update (Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM	Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire)
09:11AM	3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True (InvestorPlace)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fletcher Aaron G.L.	10% Owner	Jun 13 '25	Sale	3.09	40,000	123,600	49,957	Jun 13 07:57 PM
Kreis Leslie W.	10% Owner	Jun 13 '25	Sale	3.09	40,000	123,600	49,957	Jun 13 07:50 PM
Fletcher Aaron G.L.	10% Owner	Jun 12 '25	Sale	3.38	60,647	204,987	51,860	Jun 13 06:06 AM
Fletcher Aaron G.L.	10% Owner	Jun 11 '25	Sale	3.40	950	3,230	54,746	Jun 13 06:06 AM
Fletcher Aaron G.L.	10% Owner	Jun 10 '25	Sale	3.40	16	54	54,791	Jun 13 06:06 AM
Kreis Leslie W.	10% Owner	Jun 12 '25	Sale	3.38	60,647	204,987	51,860	Jun 13 06:01 AM
Kreis Leslie W.	10% Owner	Jun 11 '25	Sale	3.40	950	3,230	54,746	Jun 13 06:01 AM
Kreis Leslie W.	10% Owner	Jun 10 '25	Sale	3.40	16	54	54,791	Jun 13 06:01 AM
Fletcher Aaron G.L.	10% Owner	May 27 '25	Sale	3.05	21,037	64,163	56,467	May 29 09:55 PM
Fletcher Aaron G.L.	10% Owner	May 29 '25	Sale	3.03	20,200	61,206	54,792	May 29 09:55 PM
Fletcher Aaron G.L.	10% Owner	May 28 '25	Sale	2.87	15,000	43,050	55,753	May 29 09:55 PM
Kreis Leslie W.	10% Owner	May 27 '25	Sale	3.05	21,037	64,163	56,467	May 29 09:53 PM
Kreis Leslie W.	10% Owner	May 29 '25	Sale	3.03	20,200	61,206	54,792	May 29 09:53 PM
Kreis Leslie W.	10% Owner	May 28 '25	Sale	2.87	15,000	43,050	55,753	May 29 09:53 PM
Bios Fund II, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	53,454	175,864		May 27 09:00 PM
Bios Fund I QP, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	29,576	97,305		May 27 08:58 PM
Bios Fund II NT, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	25,849	85,033		May 27 08:56 PM
Bios Fund I, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	75,941	249,846		May 27 08:55 PM
Bios Fund II QP, LP	Affiliate (10% owner)	May 27 '25	Proposed Sale	3.29	105,180	346,042		May 27 08:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTRN

Lantern Pharma Inc

Upgrade your FINVIZ experience